TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: HLA typing results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Symptom Assessment Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pharmacokinetics of BTDS 5-20 ug/h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intact skin with no abnormal openings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: CAPE_V score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPAV score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: score on acoustic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin and Hematocrit values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Duodenal Contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mini International Neuropsychiatric Interview (M.I.N.I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Wisconsin Card Sorting Test (WCST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MRI - signal BOLD (Blood Oxygen Level Dependant)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Agreement with binary FFR≤0.80
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Multiple Sclerosis Related Disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of Postpartum Depression (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Number of Combined Unique Active (CUA) MRI Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quantitative determination of microorganisms (cell density: Log CFU/g)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Subjects With Treatment Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Healthy Lifestyle Behavior Scale-II
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Discharged from ICU
Endpoint domain: Mortality/survival
Primary endpoint: Failure rate of patients positioning
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of women travelling for abortion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adverse Event reporting
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients in whom esophageal balloon calibration is performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Field of view comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic range comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary artery calcification AGATSTON score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: H3 receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of unchanged TS-091
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: Maximum Observed Plasma Concentration for TAK-875
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: Maximum Observed Plasma Concentration for Glimepiride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-875
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative changes in the corneal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualitative changes in the corneal structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicities during study and for 30 days after
Endpoint domain: Adverse events/effects
Primary endpoint: Change in nocturnal oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of infants with seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Children's handwriting quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation in risk-appropriate colorectal cancer testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Differences in microbial communities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Visual Analog Scale (VAS) Score for Maximum Procedural Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction With Anesthesia (Iowa Satisfaction With Anesthesia Scale [ISAS])
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Words-in-Noise Test (WIN) Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with IUD total or partial expulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Daytime Use Assessment for dry eye symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bioavailability of experimental formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global and regional myocardial strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Plasma Methamphetamine (METH) Area Under the Curve (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Plasma Methamphetamine (METH) Maximum Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-point Major Adverse Cardiovascular Events (3P-MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Patient reported change in disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fatty acid uptake in Heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fatty acid oxidation in Heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Activities of Daily Life (ADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of Sense of Coherence (KASAM)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: muscle-tendon unit length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in BAT mass and activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of protracted-abstinence symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of depression symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of impulsive behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Completed intubation within 120 seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Assessment of auditory and verbal memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Assessment of visual and spatial memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Measurement of depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AAA diameter growth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Histological Clearance of Barrett's Metaplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum concentration of TWEAK
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with change in CTV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cytokine response of PBMC to inflammatory stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of depression risk
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of self-perceived medical errors
Endpoint domain: Adverse events/effects
Primary endpoint: pharmacokinetics of vildagliptin and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung Aeration Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Knowledge of sexual and reproductive health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sexual and reproductive health practice
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sexual and reproductive health service utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Violence against women and girls
Endpoint domain: Adverse events/effects
Primary endpoint: Interferon levels in blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ADEs
Endpoint domain: Adverse events/effects
Primary endpoint: duration of ameliorable medication side effects
Endpoint domain: Adverse events/effects
Primary endpoint: health goal adherence rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Bone Scan Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Scan Lesion Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Non-serious Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Non-cardiac chest pain symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of episodes of adverse drug reactions and adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life in the area of insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Quality of life in the area of fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: enthesitis detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical specificity in population at low risk for HIV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical sensitivity in HIV positive specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity and sensitivity in pregnant female population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity and sensitivity in pediatric population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of upper gastrointestinal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of early postoperative atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Two Year Local Control Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Verbal Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative Sensory Threshold Temperature Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Significant Functional MRI BOLD Signal Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Experiencing Adverse Events (AEs and SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of B-701 (Vofatamab) Plus Pembrolizumab Measured by ORR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Peripheral blood Immune reconstitution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage excess weight loss (%EWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: long-term effectiveness of alefacept
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: safety of alefacept
Endpoint domain: Adverse events/effects
Primary endpoint: Peak plasma concentration (Cmax) of CM082
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of CM082
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of maximum concentration (Tmax) of CM082
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half life (T1/2) of CM082
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of graft take site A vs site B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of graft take of all SASS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of graft take according to sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Serum Triglyceride Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Serum Lipoprotein Cholesterol Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Serum Apolipoprotein Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mortality in severe COVID-19 patients
Endpoint domain: Mortality/survival
Primary endpoint: AUC0-96h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Current neck pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete histological rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of AECB on patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effect and safety of moxifloxacin treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma IL-1Ra levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Posttraumatic Stress (PCL-S)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction with Life Questionnaire (SWL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: World Health Organization QOL Questionnaire (WHOQOL-BREF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total mortality at 2 years post myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Cognitive and motor function measured by time differential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Compliance of adjuvant hormonal therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 3 year biochemical progression free survival (bPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Patient needs detected
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Concordance among patient, caregiver, and team goals
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Qualitative and quantitative evaluation of palliative care services provided
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC(0-t)) of Albendazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC [0-infinity (Inf)] of Albendazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmaximum) of Albendazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre and Post Operative Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell Collection Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P-β-catenin Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of Graft Versus Host Disease (GvHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of clinical worsening events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Colony Forming Unit of total bacteria in saliva and bioaerosol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cmax of plasma budesonide and formoterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of plasma budesonide and formoterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in % Predicted Forced Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Perinatal outcomes
Endpoint domain: Mortality/survival
Primary endpoint: Regional pulmonary perfusion by EIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Regional pulmonary perfusion by CTPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in non-vellus hair count in the temple region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients diagnosed with Hepatosplenic T-cell Lymphoma
Endpoint domain: Mortality/survival
Primary endpoint: AUC of protein spectra
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asymmetry in feedback vs. feedforward network connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of SAE (serious adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of DLTs (dose limiting toxicities)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Primary Outcome Successes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of favorable outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Patency of the Treated Renal Artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: β cell mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: MMTT C-peptide at 90 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ELISA GMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients complaining cough lasting more than 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients with chronic refractory cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in personal concerns
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: safety laboratory variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12 lead electrocardiography (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants in Whom Peptic Ulcer Was Healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Standardized uptake values (SUVs) of [89Zr]Zr-BI 754111 for tumor uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Concentration of sulforaphane, alliin and their metabolites in prostate tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who experience dose limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical response in terms of optimal dose combination for further study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical tolerance in terms of additive or synergistic non-hematologic toxicities grade 2 or greater
Endpoint domain: Adverse events/effects
Primary endpoint: Average Subcutaneous Anti-Xa Blood Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in VISA-A Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of Accrual
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants that adhered to physical activity program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronal balance through range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes